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Adoptive cellular therapy is becoming an important cancer
therapy. Tumor infiltrating T cells and peripheral blood
T cells engineered to express high affinity T cell receptors
specific to tumor antigens have been effective in treating
melanoma. T cells engineered to express chimeric antigen
receptors are being used to treat cancers and hematologic
malignancies. Clinical studies have found that the charac-
teristics of cellular therapies effects clinical outcomes.
There is considerable variability between production lots
of adoptive cellular therapies. This variability affects pro-
duct characteristics and clinical outcomes. Production
variability is due to both donor and manufacturing factors.
Donor genetics as well as donor age, gender, race and
prior therapies may affect product characteristics and
function. The complexity involved with manufacturing
cellular therapies also contributes to variability in the final
product. Manufacturing adoptive cell therapies may
involve stimulation with antibodies, cytokines, growth fac-
tors or allogeneic cells; prolonged culture and expansion;
and genetic engineering. Product characteristics can affect
clinical outcomes. Several studies have found that adoptive
cellular therapies that have greater in vivo persistence and
proliferation are associated with better clinical outcomes;
however, the specific product characteristics responsible
for better or worse clinical outcomes are not well under-
stood. To better understand the critical characteristics
responsible for the clinical effectiveness of cellular thera-
pies we and others have been studying the potency of cel-
lular therapies. Specific phenotypes have been associated
with better clinical outcomes. Animal models suggest that
T memory stem cells have greater proliferative potential
and persistence than effector T cells and are more effective
for adoptive cellular therapy. We have found that high
throughput molecular assays are useful at identifying mar-
kers that are useful at measuring cell potency. In conclu-
sion, in order to improve the clinical effectiveness of
cellular therapies it’s important to better understand the
biological functions that contribute to product potency
and develop potency markers and assays to ensure that
the highest quality cells are consistently produced.
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